Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia
| Autor: | Emmanouil Nikolousis, L Ryan, L Baker, M Kaparou, Kathy Holder, J Suhr, A Kanellopoulos, Richard Lovell, E Xenou, Shankaranarayana Paneesha, Bhuvan Kishore |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Myeloid Transplantation Conditioning Graft vs Leukemia Effect Disease 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Alemtuzumab Melphalan Transplantation business.industry Hematopoietic Stem Cell Transplantation virus diseases Reduced intensity Hematology medicine.disease Leukemia Leukemia Myeloid Acute surgical procedures operative 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Stem cell business Vidarabine medicine.drug |
| Zdroj: | Bone marrow transplantation. 53(12) |
| ISSN: | 1476-5365 |
| Popis: | Allogeneic stem cell transplantation (Allo-HSCT) is sine qua non to cure high-risk acute myeloid leukaemia (AML). In spite the advent of highly active antiretroviral treatment, HIV-infected patients display a remarkable risk for haematological neoplasms such as non-Hodgkin lymphomas, Hodgkin lymphoma and acute leukaemia. Several case series have confirmed the efficacy of the autologous stem cell transplantation for the treatment of non-Hodgkin lymphomas in the HIV setting. Nonetheless, there is a paucity of data for the role of the Allo-HSCT in HIV-infected individuals with haematological malignancies. Herein, we presented the successful long-term outcome of a HIV-infected patient who received reduced intensity conditioned, matched unrelated donor transplant with alemtuzumab as graft-versus-host disease prophylaxis for therapy-related acute myeloid leukaemia. We propose that Allo-HSCT in HIV patients is safe and that alemtuzumab-based conditioning could further work to eradicate HIV in those whose donor is not CCR5 homozygous. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink